Display options
Share it on

Cell Rep. 2015 Mar 10;10(9):1487-1495. doi: 10.1016/j.celrep.2015.02.015. Epub 2015 Mar 05.

IgE/FcεRI-Mediated Antigen Cross-Presentation by Dendritic Cells Enhances Anti-Tumor Immune Responses.

Cell reports

Barbara Platzer, Kutlu G Elpek, Viviana Cremasco, Kristi Baker, Madeleine M Stout, Cornelia Schultz, Eleonora Dehlink, Kai-Ting C Shade, Robert M Anthony, Richard S Blumberg, Shannon J Turley, Edda Fiebiger

Affiliations

  1. Division of Gastroenterology and Nutrition, Boston Children's Hospital and Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA.
  2. Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
  3. Division of Gastroenterology, Brigham and Women's Hospital and Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
  4. Center for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129, USA.
  5. Division of Gastroenterology and Nutrition, Boston Children's Hospital and Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA. Electronic address: [email protected].

PMID: 25753415 PMCID: PMC4559493 DOI: 10.1016/j.celrep.2015.02.015

Abstract

Epidemiologic studies discovered an inverse association between immunoglobulin E (IgE)-mediated allergies and cancer, implying tumor-protective properties of IgE. However, the underlying immunologic mechanisms remain poorly understood. Antigen cross-presentation by dendritic cells (DCs) is of key importance for anti-tumor immunity because it induces the generation of cytotoxic CD8

Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.

References

  1. Annu Rev Immunol. 1999;17:931-72 - PubMed
  2. J Exp Med. 2000 Dec 18;192(12):1685-96 - PubMed
  3. J Immunol. 2002 Mar 1;168(5):2240-6 - PubMed
  4. Immunity. 2005 Feb;22(2):221-33 - PubMed
  5. Ann N Y Acad Sci. 2005 Nov;1058:96-104 - PubMed
  6. Nat Rev Immunol. 2007 Oct;7(10):790-802 - PubMed
  7. Nat Immunol. 2008 May;9(5):558-66 - PubMed
  8. Allergy. 2008 Oct;63(10):1255-66 - PubMed
  9. Clin Exp Immunol. 2008 Sep;153(3):401-9 - PubMed
  10. Eur J Immunol. 2008 Oct;38(10):2865-73 - PubMed
  11. Cancer Res. 2009 May 15;69(10):4319-26 - PubMed
  12. J Immunol. 2009 Oct 1;183(7):4530-6 - PubMed
  13. J Exp Med. 2010 Jun 7;207(6):1273-81 - PubMed
  14. Proc Natl Acad Sci U S A. 2011 Jun 14;108(24):9927-32 - PubMed
  15. Immunol Lett. 2011 Dec 30;141(1):36-44 - PubMed
  16. Cancer Immunol Immunother. 2012 Jul;61(7):991-1003 - PubMed
  17. Cancer Immunol Immunother. 2012 Sep;61(9):1547-64 - PubMed
  18. J Immunol. 2012 Feb 15;188(4):1840-6 - PubMed
  19. J Clin Immunol. 2012 Aug;32(4):855-65 - PubMed
  20. Nat Rev Cancer. 2012 Mar 22;12(4):265-77 - PubMed
  21. Nat Med. 2012 May 04;18(5):693-704 - PubMed
  22. Front Immunol. 2012 Jan 03;2:87 - PubMed
  23. Nat Rev Immunol. 2012 Jul 13;12(8):557-69 - PubMed
  24. Blood. 2012 Sep 6;120(10):2011-20 - PubMed
  25. J Exp Med. 2013 May 6;210(5):1035-47 - PubMed
  26. BMC Cancer. 2013 Apr 17;13:195 - PubMed
  27. Clin Cancer Res. 2013 Aug 15;19(16):4508-20 - PubMed
  28. Adv Immunol. 2013;120:1-49 - PubMed
  29. Clin Exp Allergy. 2013 Oct;43(10):1110-23 - PubMed
  30. Immunity. 2013 Nov 14;39(5):963-75 - PubMed
  31. Immunity. 2013 Nov 14;39(5):976-85 - PubMed
  32. Immunity. 2013 Dec 12;39(6):1095-107 - PubMed
  33. Nat Rev Immunol. 2014 Feb;14(2):94-108 - PubMed
  34. Curr Opin Immunol. 2014 Feb;26:63-8 - PubMed
  35. Sci Transl Med. 2014 Apr 16;6(232):232ra51 - PubMed
  36. Front Immunol. 2014 Apr 01;5:140 - PubMed
  37. Mucosal Immunol. 2015 May;8(3):516-32 - PubMed
  38. Nat Med. 1995 Jul;1(7):649-53 - PubMed
  39. J Exp Med. 1999 Jan 18;189(2):371-80 - PubMed

Publication Types

Grant support